Miguel Bergna

1.9k total citations
21 papers, 494 citations indexed

About

Miguel Bergna is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Surgery. According to data from OpenAlex, Miguel Bergna has authored 21 papers receiving a total of 494 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 14 papers in Physiology and 3 papers in Surgery. Recurrent topics in Miguel Bergna's work include Asthma and respiratory diseases (11 papers), Respiratory and Cough-Related Research (10 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (7 papers). Miguel Bergna is often cited by papers focused on Asthma and respiratory diseases (11 papers), Respiratory and Cough-Related Research (10 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (7 papers). Miguel Bergna collaborates with scholars based in Argentina, United States and Spain. Miguel Bergna's co-authors include Gustavo Zabert, Christopher L. Drake, Daniel P. Cardinali, Alejandro J. Videla, Santiago Perez‐Lloret, Daniel Pérez-Chada, Kenneth R. Chapman, Frank C. Albers, Bradley E. Chipps and Dmitry Galkin and has published in prestigious journals such as American Journal of Respiratory and Critical Care Medicine, Journal of Allergy and Clinical Immunology and SLEEP.

In The Last Decade

Miguel Bergna

18 papers receiving 474 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Miguel Bergna 292 289 99 67 48 21 494
J. Almeida 234 0.8× 234 0.8× 66 0.7× 35 0.5× 51 1.1× 21 434
Tilman Huppertz 163 0.6× 52 0.2× 36 0.4× 53 0.8× 58 1.2× 48 341
Mark Ramos 70 0.2× 16 0.1× 134 1.4× 81 1.2× 42 0.9× 29 439
Mark Berger 198 0.7× 110 0.4× 124 1.3× 19 0.3× 3 0.1× 12 333
Edilson Zancanella 237 0.8× 133 0.5× 77 0.8× 39 0.6× 2 0.0× 26 393
Justine Frija‐Masson 75 0.3× 192 0.7× 29 0.3× 20 0.3× 2 0.0× 32 357
Christine H. Heubi 227 0.8× 173 0.6× 30 0.3× 51 0.8× 21 393
Katerina Haidopoulou 62 0.2× 136 0.5× 15 0.2× 29 0.4× 2 0.0× 34 306
Christopher Kosky 82 0.3× 171 0.6× 167 1.7× 157 2.3× 26 505
Johanna Gavlak 191 0.7× 145 0.5× 31 0.3× 32 0.5× 21 463

Countries citing papers authored by Miguel Bergna

Since Specialization
Citations

This map shows the geographic impact of Miguel Bergna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miguel Bergna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miguel Bergna more than expected).

Fields of papers citing papers by Miguel Bergna

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miguel Bergna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miguel Bergna. The network helps show where Miguel Bergna may publish in the future.

Co-authorship network of co-authors of Miguel Bergna

This figure shows the co-authorship network connecting the top 25 collaborators of Miguel Bergna. A scholar is included among the top collaborators of Miguel Bergna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miguel Bergna. Miguel Bergna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Τzouvelekis, Αrgyris, Mark J. Hamblin, Won Il Choi, et al.. (2025). Late Breaking Abstract - ELEVATE IPF phase 2b open-label extension demonstrates durable efficacy of deupirfenidone. OA4456–OA4456.
2.
Maher, Toby M., Miguel Bergna, Amy Hajari Case, et al.. (2025). Deupirfenidone Compared to Placebo and Pirfenidone in Idiopathic Pulmonary Fibrosis: ELEVATE IPF Phase 2b Trial. American Journal of Respiratory and Critical Care Medicine. 211(Supplement_1). A7046–A7046. 1 indexed citations
3.
Liu, Mark C., Bradley E. Chipps, Xavier Muñoz, et al.. (2021). Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics. Respiratory Research. 22(1). 144–144. 22 indexed citations
4.
Cohen, Mark E., Alejandro Casas, Gustavo Zabert, et al.. (2021). Actualización del Plan Estratégico de la Asociación Latinoamericana de Tórax (ALAT). «Los diez mandamientos para el quinquenio 2021-2026». Archivos de Bronconeumología. 57(10). 617–620.
5.
de, María Montes, María Victorina López Varela, Eduardo Schiavi, et al.. (2020). Incorporating new evidence on inhaled medications in COPD. The latin American chest association (ALAT) 2019. Archivos de Bronconeumología. 56(2). 106–113. 10 indexed citations
6.
Albers, Frank C., Mark C. Liu, Bradley E. Chipps, et al.. (2019). Therapeutic switch from omalizumab to mepolizumab in patients with uncontrolled severe eosinophilic asthma: treatment effect by prior omalizumab treatment duration. Journal of Allergy and Clinical Immunology. 143(2). AB102–AB102. 4 indexed citations
7.
de, María Montes, María Victorina López Varela, Eduardo Schiavi, et al.. (2019). Incorporando nuevas evidencias sobre medicamentos inhalados en la EPOC. Asociación Latinoamericana de Tórax (ALAT) 2019. Archivos de Bronconeumología. 56(2). 106–113. 10 indexed citations
8.
Chapman, Kenneth R., Frank C. Albers, Bradley E. Chipps, et al.. (2019). The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. Allergy. 74(9). 1716–1726. 109 indexed citations
9.
Richeldi, Luca, Francesco Varone, Miguel Bergna, et al.. (2018). Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence. European Respiratory Review. 27(150). 180074–180074. 67 indexed citations
10.
Altman, Pablo, et al.. (2018). Patient perception of Breezhaler® and Ellipta® device feedback mechanisms in COPD: The ADVANTAGE Study. Current Medical Research and Opinion. 35(2). 221–227. 4 indexed citations
11.
Galkin, Dmitry, Mark C. Liu, Bradley E. Chipps, et al.. (2018). Efficacy and Safety of Mepolizumab in Uncontrolled Patients with Severe Eosinophilic Asthma Following a Switch from Omalizumab (OSMO Study): Exacerbation and Safety Outcomes. Journal of Allergy and Clinical Immunology. 141(2). AB409–AB409. 12 indexed citations
12.
Albers, Frank C., Mark C. Liu, Bradley E. Chipps, et al.. (2018). Efficacy and Safety of Mepolizumab in Uncontrolled Patients with Severe Eosinophilic Asthma Following a Switch from Omalizumab (OSMO Study): Asthma Control, Quality of Life and Lung Function Outcomes. Journal of Allergy and Clinical Immunology. 141(2). AB408–AB408. 6 indexed citations
13.
de, María Montes, María Victorina López Varela, Eduardo Schiavi, et al.. (2015). Guía de práctica clínica de la enfermedad pulmonar obstructiva crónica (EPOC) ALAT-2014: Preguntas y respuestas. Archivos de Bronconeumología. 51(8). 403–416. 38 indexed citations
14.
Bergna, Miguel, et al.. (2015). Development of a simple binary response questionnaire to identify airflow obstruction in a smoking population in Argentina. European Respiratory Review. 24(136). 320–326. 6 indexed citations
15.
de, María Montes, María Victorina López Varela, Eduardo Schiavi, et al.. (2015). ALAT-2014 Chronic Obstructive Pulmonary Disease (COPD) Clinical Practice Guidelines: Questions and Answers. Archivos de Bronconeumología. 51(8). 403–416. 30 indexed citations
16.
Bergna, Miguel, et al.. (2014). Obstrucción crónica de la vía aérea en un paciente de 18 años. Redalyc (Universidad Autónoma del Estado de México). 14(3). 328–337.
17.
Bergna, Miguel, et al.. (2013). Increased exhaled breath temperature in subjects with uncontrolled asthma. The International Journal of Tuberculosis and Lung Disease. 17(7). 969–972. 19 indexed citations
18.
Bergna, Miguel, et al.. (2012). Acute asthma in Buenos Aires. 40. 1010. 2 indexed citations
19.
Bergna, Miguel, et al.. (2012). Exhaled breath temperature in COPD patients. 40. 2205. 1 indexed citations
20.
Pérez-Chada, Daniel, Santiago Perez‐Lloret, Alejandro J. Videla, et al.. (2007). Sleep Disordered Breathing And Daytime Sleepiness Are Associated With Poor Academic Performance In Teenagers. A Study Using The Pediatric Daytime Sleepiness Scale (PDSS). SLEEP. 30(12). 1698–1703. 148 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. Almeida Breakdown of academic impact, for papers by Tilman Huppertz Breakdown of academic impact, for papers by Mark Ramos Breakdown of academic impact, for papers by Mark Berger Breakdown of academic impact, for papers by Edilson Zancanella Breakdown of academic impact, for papers by Justine Frija‐Masson Breakdown of academic impact, for papers by Christine H. Heubi Breakdown of academic impact, for papers by Katerina Haidopoulou Breakdown of academic impact, for papers by Christopher Kosky Breakdown of academic impact, for papers by Johanna Gavlak
Rankless by CCL
2026